A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2012
At a glance
- Drugs Ipilimumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 05 Mar 2012 Results were published in The Lancet Oncology (February 2012) journal, according to a BioSante Pharmaceuticals media release
- 19 Jan 2012 Status changed from active, no longer recruiting to discontinued.